{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:18:50Z","timestamp":1787498330000,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M683128"],"award-info":[{"award-number":["2020M683128"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012369"],"award-info":[{"award-number":["2022A1515012369"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100648"],"award-info":[{"award-number":["82100648"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870404"],"award-info":[{"award-number":["81870404"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370587"],"award-info":[{"award-number":["82370587"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.cca.2025.120147","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T19:41:52Z","timestamp":1737229312000},"page":"120147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Cytokeratin 18 fragment in liver inflammation and fibrosis: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"569","author":[{"given":"Junzhao","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-7699","authenticated-orcid":false,"given":"Bihui","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0005","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/hep.32743","article-title":"Health disparities in chronic liver disease","volume":"77","author":"Kardashian","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0010","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/hep.32741","article-title":"Attacking the public health crisis of hepatocellular carcinoma at its roots","volume":"77","author":"Lee","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cca.2025.120147_b0015","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S2468-1253(22)00238-2","article-title":"Global burden of occult hepatitis B virus infection: where we are and what to do","volume":"7","author":"Pollicino","year":"2022","journal-title":"Lancet. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhep.2022.09.001","article-title":"Loss of liver function in chronic liver disease: An identity crisis","volume":"78","author":"Berasain","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0025","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on hepatology practice: Past, present and future","volume":"76","author":"Anstee","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2025.120147_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.155115","article-title":"Cytoskeleton alterations in non-alcoholic fatty liver disease","volume":"128","author":"Pessoa","year":"2022","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.cca.2025.120147_b0035","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1007\/s00204-021-03121-0","article-title":"The application of cytokeratin-18 as a biomarker for drug-induced liver injury","volume":"95","author":"Korver","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.cca.2025.120147_b0040","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/hep.28493","article-title":"Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver","volume":"64","author":"Ku","year":"2016","journal-title":"Hepatology"},{"issue":"13\u201314","key":"10.1016\/j.cca.2025.120147_b0045","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jchromb.2011.02.039","article-title":"Application of the \u03b2-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays","volume":"879","author":"Cummings","year":"2011","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci."},{"issue":"5","key":"10.1016\/j.cca.2025.120147_b0050","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.15(5)2015.25328","article-title":"Clinical values of elevated serum cytokeratin-18 levels in hepatitis: a meta-analysis","volume":"15","author":"Yang","year":"2015","journal-title":"Hepat. Mon."},{"issue":"9","key":"10.1016\/j.cca.2025.120147_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238717","article-title":"Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS. One"},{"key":"10.1016\/j.cca.2025.120147_b0060","unstructured":"European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542."},{"issue":"8","key":"10.1016\/j.cca.2025.120147_b0065","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.14309\/ajg.0000000000002796","article-title":"TARGET-NASH investigators. High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort","volume":"119","author":"Barritt","year":"2024","journal-title":"Am. J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.cca.2025.120147_b0070","doi-asserted-by":"crossref","first-page":"e0546","DOI":"10.1097\/HC9.0000000000000546","article-title":"Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort","volume":"8","author":"Sanchez-Torres","year":"2024","journal-title":"Hepatol. Commun."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0075","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0080","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.cca.2025.120147_b0085","article-title":"Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population","volume":"8","author":"Zou","year":"2024","journal-title":"Front. Nutr."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0090","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases","volume":"47","author":"Goodman","year":"2007","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.21223","article-title":"In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease","volume":"44","author":"Wieckowska","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3748\/wjg.v13.i6.837","article-title":"Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis","volume":"13","author":"Yilmaz","year":"2007","journal-title":"World. J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.cca.2025.120147_b0105","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.cgh.2008.07.016","article-title":"Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients","volume":"6","author":"Diab","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0110","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/gut.2007.123943","article-title":"Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection","volume":"57","author":"Papatheodoridis","year":"2008","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.cca.2025.120147_b0115","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1007\/s11695-008-9506-y","article-title":"A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)","volume":"18","author":"Younossi","year":"2008","journal-title":"Obes. Surg."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0120","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"issue":"23\u201324","key":"10.1016\/j.cca.2025.120147_b0125","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.cca.2010.08.035","article-title":"Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B","volume":"411","author":"Eren","year":"2010","journal-title":"Clin. Chim. Acta."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.23255","article-title":"Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation","volume":"51","author":"Musso","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0135","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11695-010-0204-1","article-title":"A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis","volume":"21","author":"Younossi","year":"2011","journal-title":"Obes. Surg."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0140","first-page":"347","article-title":"A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis","volume":"63","author":"Grigorescu","year":"2012","journal-title":"J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0145","first-page":"772","article-title":"Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery","volume":"107","author":"Pirvulescu","year":"2012","journal-title":"Chirurgia. (bucur)."},{"issue":"11\u201312","key":"10.1016\/j.cca.2025.120147_b0150","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/apt.12091","article-title":"Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers","volume":"36","author":"Shen","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0155","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jcv.2013.10.008","article-title":"Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection","volume":"58","author":"Bae","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"9","key":"10.1016\/j.cca.2025.120147_b0160","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/ajg.2013.168","article-title":"Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children","volume":"108","author":"Feldstein","year":"2013","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3350\/cmh.2013.19.2.120","article-title":"Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease","volume":"19","author":"Kim","year":"2013","journal-title":"Clin. Mol. Hepatol."},{"issue":"11","key":"10.1016\/j.cca.2025.120147_b0170","first-page":"4191","article-title":"Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease","volume":"7","author":"Aida","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"9","key":"10.1016\/j.cca.2025.120147_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105903","article-title":"Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis\u2013a comparison with routine biochemical markers","volume":"9","author":"Chan","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.cca.2025.120147_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111551","article-title":"Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice\u2013an exploratory case-control study","volume":"9","author":"Dvorak","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0185","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1159\/000439076","article-title":"Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population","volume":"33","author":"Hasegawa","year":"2015","journal-title":"Dig. Dis."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0190","doi-asserted-by":"crossref","first-page":"837","DOI":"10.5604\/16652681.1171767","article-title":"Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease","volume":"14","author":"Kawanaka","year":"2015","journal-title":"Ann. Hepatol."},{"issue":"3","key":"10.1016\/j.cca.2025.120147_b0195","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/ajg.2015.29","article-title":"Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation","volume":"110","author":"Walenbergh","year":"2015","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131664","article-title":"Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS. One"},{"issue":"44","key":"10.1016\/j.cca.2025.120147_b0205","doi-asserted-by":"crossref","first-page":"9844","DOI":"10.3748\/wjg.v22.i44.9844","article-title":"Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population","volume":"22","author":"Liu","year":"2016","journal-title":"World. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0210","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.gastre.2017.02.003","article-title":"Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population","volume":"40","author":"Arab","year":"2017","journal-title":"Gastroenterolog\u00eda. y. Hepatolog\u00eda. (english. Edition)."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ajg.2017.05.008","article-title":"Relationship between liver injury and serum cytokeratin 18 levels in asymptomatic hepatitis B virus carriers and in patients with chronic hepatitis B infection","volume":"18","author":"Balkan","year":"2017","journal-title":"Arab. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0220","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000480142","article-title":"Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients","volume":"35","author":"Kobayashi","year":"2017","journal-title":"Dig. Dis."},{"key":"10.1016\/j.cca.2025.120147_b0225","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/CEG.S135526","article-title":"Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B","volume":"10","author":"Li","year":"2017","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.cca.2025.120147_b0230","first-page":"1","article-title":"A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease","volume":"2017","author":"Liang","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0235","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1038\/s41598-017-05257-5","article-title":"Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease","volume":"7","author":"Wu","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0240","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc19-1071","article-title":"Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes","volume":"43","author":"Bril","year":"2020","journal-title":"Diabetes. Care"},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0245","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001174","article-title":"Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels","volume":"8","author":"Zheng","year":"2020","journal-title":"BMJ Open. Diabetes. Res. Care."},{"issue":"11","key":"10.1016\/j.cca.2025.120147_b0250","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/MEG.0000000000002176","article-title":"Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"33","author":"Tada","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0255","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/apt.17515","article-title":"Non-invasive diagnosis of alcohol-related steatohepatitis in patients ongoing alcohol withdrawal based on cytokeratin 18 and transient elastography","volume":"58","author":"Chalin","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cca.2025.120147_b0260","first-page":"341","article-title":"Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin. Med. J. (engl)."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0265","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/10520295.2024.2385011","article-title":"Association between serum cytokeratin 18 and N-terminal procollagen III propeptide in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"99","author":"Kaya","year":"2024","journal-title":"Biotech. Histochem."},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","article-title":"A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell. Metab."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0275","doi-asserted-by":"crossref","first-page":"563","DOI":"10.18388\/abp.2011_2225","article-title":"Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease","volume":"58","author":"Lebensztejn","year":"2011","journal-title":"Acta. Biochim. Pol."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0280","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/MEG.0000000000000342","article-title":"Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Ergelen","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131658","article-title":"Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis","volume":"10","author":"Sekiguchi","year":"2015","journal-title":"PLoS. One"},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0290","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPG.0000000000001136","article-title":"Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease","volume":"63","author":"Mandelia","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0295","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.dld.2015.09.008","article-title":"Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis","volume":"48","author":"Rosso","year":"2016","journal-title":"Dig. Liver. Dis."},{"issue":"5","key":"10.1016\/j.cca.2025.120147_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174394","article-title":"Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients","volume":"12","author":"Huang","year":"2017","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.cca.2025.120147_b0305","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00795-018-0184-0","article-title":"Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis","volume":"51","author":"Hayashi","year":"2018","journal-title":"Med. Mol. Morphol."},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5009\/gnl18037","article-title":"Plasma Levels of K18 Fragments Do Not Correlate with Alcoholic Liver Fibrosis","volume":"13","author":"Schlossberger","year":"2019","journal-title":"Gut. Liver."},{"issue":"3","key":"10.1016\/j.cca.2025.120147_b0315","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/liv.14776","article-title":"Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD","volume":"41","author":"Kimura","year":"2021","journal-title":"Liver. Int."},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0320","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12876-021-01963-7","article-title":"Cytokeratin 18 can help predict liver fibrosis in HCV infected patients with type 2 diabetes mellitus","volume":"21","author":"Li","year":"2021","journal-title":"BMC. Gastroenterol."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0325","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/acer.15081","article-title":"Serum keratin 18-M65 levels detect progressive forms of alcohol-associated liver disease in early noncirrhotic stages","volume":"47","author":"Maccioni","year":"2023","journal-title":"Alcohol. Clin. Exp. Res. (hoboken)."},{"issue":"23","key":"10.1016\/j.cca.2025.120147_b0330","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038342","article-title":"Clinical significance of serum Ck18-M65 and M30 levels in patients with chronic hepatitis B combined with nonalcoholic steatohepatitis and liver fibrosis","volume":"103","author":"Dai","year":"2024","journal-title":"Medicine. (Baltimore)"},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0335","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/MPG.0b013e3181e376be","article-title":"Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD","volume":"51","author":"Fitzpatrick","year":"2010","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0340","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MCG.0b013e3181c0945a","article-title":"Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease","volume":"44","author":"Papatheodoridis","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0345","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.24734","article-title":"Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis","volume":"55","author":"Joka","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066328","article-title":"Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis","volume":"8","author":"Kamada","year":"2013","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0355","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2013.07.042","article-title":"Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease","volume":"60","author":"Cusi","year":"2014","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0360","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/liv.12297","article-title":"Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C","volume":"34","author":"Parfieniuk-Kowerda","year":"2014","journal-title":"Liver. Int."},{"issue":"12","key":"10.1016\/j.cca.2025.120147_b0365","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.dld.2016.07.037","article-title":"Serum hepatocyte apoptosis biomarker predicts the presence of significant histological lesion in chronic hepatitis B virus infection","volume":"48","author":"Cao","year":"2016","journal-title":"Dig. Liver. Dis."},{"issue":"3","key":"10.1016\/j.cca.2025.120147_b0370","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10620-015-3916-1","article-title":"Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH","volume":"61","author":"Pimentel","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.cca.2025.120147_b0375","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3480234","article-title":"Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease","volume":"2017","author":"Swiderska","year":"2017","journal-title":"Mediators. Inflamm."},{"issue":"6","key":"10.1016\/j.cca.2025.120147_b0380","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/MEG.0000000000001079","article-title":"Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina","volume":"30","author":"Valva","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0385","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jmri.28040","article-title":"The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis","volume":"56","author":"Alsaqal","year":"2022","journal-title":"J. Magn. Reson. Imaging."},{"issue":"7","key":"10.1016\/j.cca.2025.120147_b0390","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41390-021-01666-5","article-title":"Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease","volume":"91","author":"Manco","year":"2022","journal-title":"Pediatr. Res."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0395","article-title":"The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy","volume":"58","author":"Mikolasevic","year":"2022","journal-title":"Medicina. (kaunas)"},{"issue":"12","key":"10.1016\/j.cca.2025.120147_b0400","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1002\/hep4.2075","article-title":"Serum keratin-18 detects hepatic inflammation and predicts progression in compensated alcohol-associated liver disease","volume":"6","author":"Thorhauge","year":"2022","journal-title":"Hepatol. Commun."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0405","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4093\/dmj.2023.0189","article-title":"A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease","volume":"48","author":"Choi","year":"2024","journal-title":"Diabetes. Metab. J."},{"issue":"2","key":"10.1016\/j.cca.2025.120147_b0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263989","article-title":"Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation","volume":"17","author":"Stoffers","year":"2022","journal-title":"PLoS. One"},{"issue":"11","key":"10.1016\/j.cca.2025.120147_b0415","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.14309\/ajg.0000000000000912","article-title":"In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers","volume":"115","author":"Atkinson","year":"2020","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.cca.2025.120147_b0420","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/erm.10.14","article-title":"Utilization of cytokeratin-based biomarkers for pharmacodynamic studies","volume":"10","author":"Linder","year":"2010","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0425","doi-asserted-by":"crossref","DOI":"10.3390\/biom13040675","article-title":"Plasma Cytokeratin-18 Fragment Level Reflects the Metabolic Phenotype in Obesity","volume":"13","author":"Goralska","year":"2023","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.cca.2025.120147_b0430","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2023.05.025","article-title":"Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis","volume":"79","author":"Elkrief","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.cca.2025.120147_b0435","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/liv.14699","article-title":"CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission","volume":"41","author":"Derben","year":"2021","journal-title":"Liver. Int."},{"key":"10.1016\/j.cca.2025.120147_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101547","article-title":"Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"51","author":"Cao","year":"2022","journal-title":"EClinicalMedicine."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125000269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125000269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:06:04Z","timestamp":1740362764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125000269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":88,"alternative-id":["S0009898125000269"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120147","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokeratin 18 fragment in liver inflammation and fibrosis: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120147"}}